MedTrace Logo

Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis

NCT00345137 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2006-06-27

No results posted yet for this study

Summary

The study tests the hypothesis that systemic and renal nitric oxide availability is changed in polycystic kidney disease and chronic glomerulonephritis.

Conditions

Interventions

DRUG

Ng-monomethyl-L-arginine (drug)

Sponsors & Collaborators

  • Regional Hospital Holstebro

    lead OTHER

Principal Investigators

  • Erling B Pedersen, Professor · Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark

  • Jesper N Bech, MD, Ph.d. · Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00345137 on ClinicalTrials.gov